Drugs / 166Ho-DOTMP
166Ho-DOTMP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00083564 | Mar 2004 → ? | plasma cell myeloma | Poniard Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 166Ho-DOTMP | “STR (Skeletal Targeted Radiotherapy, 166Ho-DOTMP) is an investigational radiopharmaceutical that delivers radiation directly to cancer cells in the bone and bone marrow.” NCT00083564 ↗ |
| Known as | Skeletal Targeted Radiotherapy | “STR (Skeletal Targeted Radiotherapy, 166Ho-DOTMP) is an investigational radiopharmaceutical that delivers radiation directly to cancer cells in the bone and bone marrow.” NCT00083564 ↗ |
| Known as | STR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083564 ↗ |
| Modality | Other / unclassified | “investigational radiopharmaceutical” NCT00083564 ↗ |
| Route | Intravenous | “750 mCi/m2 166Ho DOTMP intravenously” NCT00083564 ↗ |